By: Benzinga
UPDATE: Citigroup Reiterates on Amgen Following Detailed Market Analysis
In a report published Friday, Citigroup analyst Yaron Werber reiterated a Buy rating on Amgen (NASDAQ: AMGN ), but lowered the price target from $139.00 to $131.00. In the report, Citigroup noted, “We conducted a detailed analysis of the myeloma market and conclude that Kyprolis/oprozomib are facing tremendous long-term headwinds
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here